Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Priyam Shah - Head of Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Lucas Baranowski - UBS Rachel Vatnsdal - JPMorgan Chase Mark Massaro - BTIG Edmund Tu - Morgan Stanley Tim Chiang - Capital One David Westenberg - Piper Sandler Mason Carrico - Stephens Inc. Operator Good day and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) D ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Priyam Shah - Investor Relations Brian McKelligon - Chief Executive Officer John Ek - Chief Financial Officer Conference Call Participants Tim Chiang - Capital One Mason Carrico - Stephens Inc Ruizhi Qin - JPMorgan Vivian Bais - BTIG Kyle Mikson - Canaccord Genuity David Westenberg - Piper Sandler Lucas Baranowski - UBS Operator Good day and thank you for standing by. Welcome to the Akoya Biosc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

Financial Data and Key Metrics Changes - Akoya reported record revenue of $21.2 million in Q4 2022, representing a 31% growth over Q4 2021, and full-year revenue of $74.9 million, a 36% increase over the previous year [22][30] - Gross profit for Q4 was $12 million, with a full-year gross margin of 58% [27] - Operating expenses totaled $29.6 million for Q4 and $109.5 million for the full year, reflecting significant investments in business expansion [28] Business Line Data and Key Metrics Changes - Product revenue, including instruments, reagents, and software, was $15.7 million for Q4 and $57.7 million for the full year, marking a 30% growth year-over-year [22] - Instrument revenue was $11.1 million for Q4 and $38.6 million for the full year, representing a 35% increase year-over-year [23] - Reagent revenue was $4.5 million for Q4 and $18.4 million for the full year, showing a 29% growth over the previous year [24] Market Data and Key Metrics Changes - The installed base of instruments reached 934 by the end of 2022, with 71 instruments sold in Q4 and 237 for the full year, a 61% growth in placements from the prior year [8][30] - The company has the largest installed base of spatial instruments in the industry, with a target to reach 1,000 instruments early in 2023 [8] Company Strategy and Development Direction - Akoya aims to enhance its leadership in spatial biology by introducing platform and workflow improvements across its instrument line, focusing on operational efficiencies and targeted investments in 2023 [10][20] - The company plans to expand its product offerings with the launch of PhenoCode panels and improvements to existing systems, which are expected to drive reagent pull-through and increase revenue [11][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the spatial biology market, citing strong commercial execution and a growing installed base as key drivers for future performance [8][20] - The company provided preliminary revenue guidance for 2023 in the range of $95 million to $98 million, anticipating continued growth despite macroeconomic challenges [31] Other Important Information - Akoya's Advanced BioPharma Solutions CLIA Lab is gaining traction with large pharma partners, contributing to service revenue growth [26] - The company is focused on partnerships with leading biopharma and diagnostic leaders to drive the adoption of its products in clinical diagnostics [20] Q&A Session Summary Question: Can you provide insights on the 2023 guidance regarding instrument pull-through and consumable mix? - Management indicated that while many customers are not yet at full utilization of the PhenoCycler Fusion, they expect gradual increases in pull-through as more customers become fully operational [33][35] Question: What is the current cash position and any potential financing plans? - The company reported $81 million in cash and $11 million in additional debt capacity, indicating a solid cash position for continued growth [36][37] Question: What factors contributed to the reagent revenue performance in Q4? - Management noted that COVID lockdowns in China and currency issues in Europe impacted reagent revenue, but order volumes have picked up in Q1 2023 [51][53] Question: How is the company addressing the elongation of capital purchase timelines? - Management acknowledged some elongation in capital purchase timelines, particularly in EMEA, but did not anticipate a material impact on overall performance [55][57] Question: What is the expected contribution of new products to the 2023 revenue guidance? - Management indicated that while new products like the PhenoCode panels will contribute, the overall impact is modest, with a focus on driving reagent revenue growth through existing products [70][74]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 (Address of principal executive offices) (Zip Code) (855) 896-8401 Registrant's tele ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Priyam Shah - Senior Director, Investor Relations Brian McKelligon - Chief Executive Officer Joseph Driscoll - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens Mark Massaro - BTIG Neil Vibhakar - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2022 Earnings Conference Call. At this time, all partici ...

Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Priyam Shah - Head of IR Brian McKelligon - CEO Joseph Driscoll - CFO Conference Call Participants Neil Vibhakar - Morgan Stanley Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG David Westenberg - Piper Sandler Operator Thank you for standing by, and welcome to the Akoya Biosciences Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. Af ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) 4 ...